Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Krystal Biotech (KRYS) over the last 6 years, with Dec 2024 value amounting to $6.1 million.

  • Krystal Biotech's Gains from Investment Securities fell 99.21% to $18,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $14.8 million, marking a year-over-year increase of 132.77%. This contributed to the annual value of $6.1 million for FY2024, which is 19.19% up from last year.
  • Per Krystal Biotech's latest filing, its Gains from Investment Securities stood at $6.1 million for FY2024, which was up 19.19% from $5.1 million recorded in FY2023.
  • Krystal Biotech's 5-year Gains from Investment Securities high stood at $6.1 million for FY2024, and its period low was $934,000 during FY2020.
  • For the 3-year period, Krystal Biotech's Gains from Investment Securities averaged around $4.2 million, with its median value being $5.1 million (2023).
  • As far as peak fluctuations go, Krystal Biotech's Gains from Investment Securities plummeted by 69.54% in 2020, and later spiked by 370.66% in 2021.
  • Over the past 5 years, Krystal Biotech's Gains from Investment Securities (Yearly) stood at $934,000 in 2020, then skyrocketed by 370.66% to $4.4 million in 2021, then crashed by 64.60% to $1.6 million in 2022, then surged by 227.25% to $5.1 million in 2023, then grew by 19.19% to $6.1 million in 2024.